Tuesday, November 2, 2021

Enhertu scores ‘impressive’ new data in HER2+ breast cancer

AstraZeneca’s has reported updated results from a phase II trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy in patients with HER2-positive metastatic breast cancer.

The phase II DESTINY-Breast01 trial is evaluating Enhertu (trastuzumab deruxtecan) in HER2-positive metastatic breast cancer following two or more prior HER2-based regimens.

The updated data, with a median duration of follow-up of 20.5 months, demonstrated that patients treated with Enhertu achieved an objective response rate (ORR) of 61.4% and a median duration of response (DoR) of 20.8 months.

In addition, the median progression-free survival (PFS) was 19.4 months, with an exploratory landmark analysis of overall survival (OS) also showing that an estimated 74% of patients remained alive at 18 months.

Prior analysis at 11.1 months of follow-up found an ORR of 60.9% and a median DoR of 14.8 months, as well as a median PFS of 16.4 months.

“These results reinforce the transformational potential of Enhertu in patients with previously treated HER2-positive metastatic breast cancer,” said José Baselga, executive vice president, Oncology R&D at AZ.

“With a median duration of response of greater than twenty months, the updated results of DESTINY-Breast01 are unprecedented. We look forward to further confirming the DESTINY-Breast01 findings with results from our phase III development programme for Enhertu,” he added.

Enhertu is approved in the US and Japan for the treatment of HER2-positive, unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens in the metastatic setting.

AZ is continuing to study Enhertu in a number of ongoing phase III trials in patients with HER2-expressing metastatic breast cancer.

This includes the DESTINY-Breast02 study, which is evaluating Enhertu as a third-line treatment for patients with HER2-positive metastatic breast cancer and the DESTINY-Breast03 which is testing Enhertu in the second-line setting.

Another study, DESTINY-Breast04, is investigating Enhertu in patients with metastatic breast cancer and low expressions of HER2.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...